GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Recommendation of “Hold” by Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been given a consensus recommendation of “Hold” by the fifteen research firms that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $3.8125.

GDRX has been the subject of several research reports. Citigroup lifted their price target on shares of GoodRx from $3.50 to $4.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. The Goldman Sachs Group restated a “neutral” rating and set a $3.50 price objective on shares of GoodRx in a report on Friday, May 8th. Wells Fargo & Company reduced their price objective on shares of GoodRx from $7.00 to $3.50 and set an “overweight” rating for the company in a report on Wednesday, March 4th. TD Cowen boosted their target price on shares of GoodRx from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Finally, Weiss Ratings lowered shares of GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 20th.

GoodRx Stock Up 6.3%

GDRX stock opened at $3.06 on Thursday. The stock’s 50 day simple moving average is $2.65 and its 200 day simple moving average is $2.48. GoodRx has a fifty-two week low of $1.77 and a fifty-two week high of $5.81. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.47 and a current ratio of 1.47. The company has a market cap of $1.05 billion, a P/E ratio of 51.01, a price-to-earnings-growth ratio of 1.33 and a beta of 1.60.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.07. The business had revenue of $194.01 million for the quarter, compared to analyst estimates of $185.40 million. GoodRx had a return on equity of 7.90% and a net margin of 2.61%.The company’s quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.09 earnings per share. On average, research analysts expect that GoodRx will post 0.17 earnings per share for the current fiscal year.

Institutional Trading of GoodRx

Several institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC lifted its holdings in shares of GoodRx by 124.4% in the first quarter. AQR Capital Management LLC now owns 282,320 shares of the company’s stock valued at $1,245,000 after purchasing an additional 156,482 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in GoodRx by 7.5% during the first quarter. Goldman Sachs Group Inc. now owns 783,378 shares of the company’s stock worth $3,455,000 after buying an additional 54,783 shares in the last quarter. Jane Street Group LLC purchased a new stake in GoodRx in the 1st quarter valued at $370,000. Creative Planning bought a new position in GoodRx during the 2nd quarter valued at $93,000. Finally, Cetera Investment Advisers bought a new position in GoodRx during the 2nd quarter valued at $50,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.